WO2003082187A3 - Purification et clonage de nmn adenylyltranserase et son utilisation therapeutique - Google Patents

Purification et clonage de nmn adenylyltranserase et son utilisation therapeutique Download PDF

Info

Publication number
WO2003082187A3
WO2003082187A3 PCT/US2003/007563 US0307563W WO03082187A3 WO 2003082187 A3 WO2003082187 A3 WO 2003082187A3 US 0307563 W US0307563 W US 0307563W WO 03082187 A3 WO03082187 A3 WO 03082187A3
Authority
WO
WIPO (PCT)
Prior art keywords
nmnat
modifying
composition
adenylyltranserase
nmn
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2003/007563
Other languages
English (en)
Other versions
WO2003082187A2 (fr
Inventor
Hiremagalur N Jayaram
Joel A Yalowitz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Indiana University Bloomington
Original Assignee
Indiana University Bloomington
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Indiana University Bloomington filed Critical Indiana University Bloomington
Priority to AU2003220201A priority Critical patent/AU2003220201A1/en
Publication of WO2003082187A2 publication Critical patent/WO2003082187A2/fr
Publication of WO2003082187A3 publication Critical patent/WO2003082187A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1241—Nucleotidyltransferases (2.7.7)

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne une composition conçue pour modifier la production de NAD. Cette composition comprend un composant qui modifie les NMNAT ainsi qu'un excipient pharmaceutiquement acceptable. L'invention se rapporte également à une séquence d'ADN complémentaire codant les NMNAT. L'invention concerne par ailleurs un procédé permettant de traiter par exemple un diabète, un cancer, un infarctus du myocarde, un accident vasculaire cérébral, des troubles neurodégénératifs, un choc, et le vieillissement, par administration à un patient d'une dose efficace d'une composition conçue pour modifier la production de NAD. L'invention se rapporte en outre à une thérapie génique faisant appel à une séquence codant les NMNAT et un procédé permettant d'introduire cette séquence efficacement dans le génome d'un hôte.
PCT/US2003/007563 2002-03-26 2003-03-13 Purification et clonage de nmn adenylyltranserase et son utilisation therapeutique Ceased WO2003082187A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2003220201A AU2003220201A1 (en) 2002-03-26 2003-03-13 Purification and cloning of nmn adenylyltranserase and its therapeutic use

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US36807802P 2002-03-26 2002-03-26
US60/368,078 2002-03-26

Publications (2)

Publication Number Publication Date
WO2003082187A2 WO2003082187A2 (fr) 2003-10-09
WO2003082187A3 true WO2003082187A3 (fr) 2003-12-04

Family

ID=28675440

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2003/007563 Ceased WO2003082187A2 (fr) 2002-03-26 2003-03-13 Purification et clonage de nmn adenylyltranserase et son utilisation therapeutique

Country Status (2)

Country Link
AU (1) AU2003220201A1 (fr)
WO (1) WO2003082187A2 (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009108999A1 (fr) 2008-03-03 2009-09-11 Ross Stewart Grant Formulations pharmaceutiques de resvératrol et procédés d'utilisation de celles-ci pour traiter des troubles cellulaires
GB201006961D0 (en) * 2010-04-27 2010-06-09 Babraham Inst NMN modulator
EP2584041A1 (fr) * 2011-10-21 2013-04-24 Industrial Cooperation Foundation Chonbuk National University Composition pour prévenir ou traiter le diabète comprenant un inhibiteur nad glycohydrolase comme ingrédient actif
IN2014DN05803A (fr) 2011-12-14 2015-05-15 Univ Texas
WO2013130672A2 (fr) * 2012-02-27 2013-09-06 United States Of America As Represented By The Department Of Veterans Affairs Traitements et diagnostics améliorés du cancer
CN104487575B (zh) * 2012-07-28 2017-09-19 深圳华大基因股份有限公司 Nmnat1突变基因、检测其的引物、试剂盒和方法以及其用途
CN103710321B (zh) * 2013-12-31 2015-04-01 邦泰生物工程(深圳)有限公司 烟酰胺单核苷酸腺苷转移酶突变体及其编码基因和应用
CN107475139A (zh) * 2017-09-30 2017-12-15 广州大学 一种pH稳定型发酵培养基及其应用

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
BALDUCCI ET AL.: "Assay methods for nicotinamide mononucleotide adenyltransferase of wide applicability", ANALYTICAL BIOCHEMISTRY, vol. 228, 1995, pages 64 - 68, XP002970567 *
RAFFAELLI ET AL.: "Identification of a novel human nicotinamide mononucleotide adenyltransferase", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATION, vol. 297, 2002, pages 835 - 840, XP002243554 *
ROSENBERG ET AL.: "Gene therapist, heal thyself", SCIENCE, vol. 287, March 2000 (2000-03-01), pages 1751, XP002954000 *
WOOD ET AL.: "The genome of the natural genetic engineer agrobacterium tumefaciens C58", SCIENCE, vol. 294, December 2001 (2001-12-01), pages 2317 - 2323, XP002226726 *

Also Published As

Publication number Publication date
AU2003220201A1 (en) 2003-10-13
WO2003082187A2 (fr) 2003-10-09
AU2003220201A8 (en) 2003-10-13

Similar Documents

Publication Publication Date Title
AU2005202257C1 (en) Azacyclic compounds for use in the treatment of serotonin related diseases
WO2002066477A3 (fr) Composes
GB2405147A (en) Therapeutic molecules and methods-1
WO2003079979A3 (fr) Procede de traitement d'insuffisance cardiaque globale
WO2002065979A3 (fr) Nouveaux composes de pyrimidine
TNSN07048A1 (en) Trifluoromethyl substituted benzamides as kinase inhibitors
PT1928499E (pt) Utilização de um inibidor da dpp-iv para reduzir eventos hipoglicémicos
WO2004069190A3 (fr) Therapie combinee destinee au traitement de troubles associes a une carence proteique
WO2004037768A3 (fr) Composes a usage medicinal
WO2004037181A3 (fr) Inhibiteurs de dipeptidyl peptidase iv a base de glycinenitrile et procedes correspondants
WO2004045618A3 (fr) Nouveaux medicaments destines au traitement de la bronchopneumopathie chronique obstructive
IL160028A (en) Thiophene carboxamide derivatives, process for their preparation, pharmaceutical compositions comprising them and their use in therapy
AU2003282215A1 (en) Anti-cancer composition comprising dmxaa or related compound
WO2009025760A3 (fr) Compositions de phénylalanine ammoniac/lyase procaryotiques et des procédés de traitement du cancer en utilisant des compositions de celles-ci
SI1551409T1 (sl) Uporaba kinazolinskega derivata ZD6474, kombiniranega z gemcitabinom in po želji ionizirajočim obsevanjem, pri zdravljenju raka
WO2005033099A3 (fr) Nouveaux inhibiteurs de dipeptidylpeptidase iv, leurs procedes de preparation et compositions les contenant
WO2003002593A3 (fr) Structures peptidiques utiles pour la modulation competitive de la catalyse de dipeptidyle peptidase iv
TW200510375A (en) New compounds
TW200744636A (en) Combined treatment with and composition of 6,6-bicyclic ring substituted heterobicyclic protein kinase inhibitor and anti-cancer agents
MXPA04004355A (es) Tratamiento de combinacion que comprende zd6474 y un taxano.
DE60305514D1 (de) Neue verwendung von benzothiazolderivaten
WO2003082187A3 (fr) Purification et clonage de nmn adenylyltranserase et son utilisation therapeutique
AU2002303214A1 (en) Lps-responsive chs1/beige-like anchor gene and therapeutic applications thereof
SI1594885T1 (sl) Zdravilo za inhibiranje rasti tumorjev
CA2470731A1 (fr) Agonistes du recepteur de facteur 2 de liberation de la corticotropine

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP